The Role of Muscle Protein and Energy Metabolism in Statin-Associated Muscle Symptoms

Flemming Dela, Joanne Mallinson, Paul L. Greenhaff

Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

Abstract

Animal models of overt statin myopathy reveal clear negative effects on muscle protein and carbohydrate metabolism, which appear to be linked to changes in Akt/FOXO signalling. Forcibly increasing muscle carbohydrate flux under these conditions by pharmacological means blocks statin myopathy. Human volunteer research has delivered less definitive mechanistic insight of the aetiology of statin-related metabolic dysregulation, with little evidence of profound changes in muscle protein and carbohydrate metabolism to date in statin myalgia. However, this may be at least partly explained by statin myalgic patients stopping or changing statin medication before overt muscle pathology has developed to anything like that resembling overt muscle myopathy. Several lines of evidence have associated statin therapy with increased risk of new-onset diabetes and dysregulation of glucose control, but the mechanisms underpinning these observations are currently unresolved.
Original languageEnglish
Title of host publicationStatin-Associated Muscle Symptoms. Contemporary Cardiology
EditorsPaul D. Thompson, Beth A. Taylor
PublisherSpringer
Publication date2020
Pages113-120
ISBN (Print) 978-3-030-33303-4
ISBN (Electronic)978-3-030-33304-1
Publication statusPublished - 2020
SeriesContemporary Cardiology

Cite this